Prudential PLC Biomarin Pharmaceutical Inc Transaction History

Prudential PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $1,448 - $1,871	-19 Reduced 0.27%	7,053 $680,000
Q3 2023 Nov 09, 2023	SELL	$85.07 - $94.48 $141,046 - $156,647	-1,658 Reduced 18.99%	7,072 $625,000
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $8,147 - $9,428	-94 Reduced 1.07%	8,730 $756,000
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $122,397 - $163,591	1,395 Added 18.78%	8,824 $858,000
Q4 2022 Feb 08, 2023	BUY	$80.93 - $108.63 $291,267 - $390,959	3,599 Added 93.97%	7,429 $768,000
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $1.01 Million - $1.19 Million	-12,293 Reduced 76.25%	3,830 $325,000
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $479,487 - $582,589	-6,708 Reduced 29.38%	16,123 $1.34 Million
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $219,274 - $273,620	2,952 Added 14.85%	22,831 $1.76 Million
Q4 2021 Feb 11, 2022	SELL	$71.72 - $91.47 $49,558 - $63,205	-691 Reduced 3.36%	19,879 $1.76 Million
Q3 2021 Nov 10, 2021	BUY	$74.77 - $85.47 $1.54 Million - $1.76 Million	20,570 New	20,570 $1.59 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Prudential PLC, based on Form 13F filings with the SEC.

Stay updated on Prudential PLC with notifications on news.